Jordyn Sava

Adagrasib shows early signs of activity and tolerability in patients with STK11/KRAS G12C–mutated non–small cell lung cancer.

Patients with HRR-deficient metastatic castration-resistant prostate cancer saw a 14-month boost in OS and a 38% lower risk of death with talazoparib plus enzalutamide.

First-line nivolumab plus ipilimumab was shown to be effective and well-tolerated in patients with unresectable hepatocellular carcinoma in the CheckMate 9DW study.

Ropeginterferon alfa-2b showed superior efficacy over anagrelide in the SURPASS-ET trial for essential thrombocythemia, with higher durable response rates and greater JAK2 allele burden reduction.

Treatment sequencing with targeted therapies may help to improve overall survival, according to real-world data.

Ensartinib has received FDA approval for the first-line treatment of ALK-positive locally advanced or metastatic non–small cell lung cancer.

Most patients with triple-negative breast cancer experienced a protocol-defined immune response with an investigational vaccine, phase 1 data showed.

NCCN guidelines have been updated to recommend imetelstat to treat symptomatic anemia in patients with lower-risk myelodysplastic syndromes.

Many symptoms related to endometrial cancer may improve within 1 year in women with endometrial cancer, with the exception of those with high-risk disease.

Liso-cel may be an effective treatment option for relapsed/refractory mantle cell lymphoma, including those with high-risk features who have limited treatment options.

First-line treatment with nivolumab plus ipilimumab for patients with microsatellite instability–high or mismatch repair deficient metastatic colorectal cancer can be considered a standard-of-care option based on results from the phase 3 CheckMate-8HW trial.

Treatment with belzutifan for advanced/metastatic clear cell renal cell carcinoma delayed worsening symptoms and improved quality of life.

Steroids are the standard approach in immune-related adverse events; however, some experts maintain that other management strategies are needed.

The duration of response was 39.2 months among patients with 1 metastatic site treated in the combination arm vs 29.5 months for patients given sunitinib.

Data suggest that frontline treatment brentuximab vedotin elicits superior outcomes in patients with Hodgkin Lymphoma, regardless of PET2 results.

Quizartinib plus standard intensive induction and consolidation therapy was associated with longer survival rates in patients with FLT3-ITD–positive acute myeloid leukemia.

For patients receiving an aromatase inhibitor for hormone receptor–positive, HER2-negative breast cancer, the addition of abemaciclib doubled median progression-free survival vs placebo.